News - Johnson & Johnson, Anti-Arthritics/Rheumatics


Popular Filters

Janssen pulls EU application for IV Simponi


Janssen Biologics, a European subsidiary of US health care giant Johnson & Johnson, says it has withdrawn…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonRegulationSimponi Injection

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis


Final draft guidance from the UK health care costs watchdog the National Institute for Health and Care…

Anti-Arthritics/RheumaticsJanssenJohnson & JohnsonNorthern EuropePharmaceuticalPricingRegulationStelara InjectionUK

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsEuropeJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelara InjectionUK

Mitsubishi Tanabe succeeds in arbitration


Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) says it has been awarded $117 million in an…

Anti-Arthritics/RheumaticsAsia-PacificJanssen BiotechJohnson & JohnsonLicensingMitsubishi TanabePharmaceuticalPricingRemicade

Simponi ARIA cleared by US FDA


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Biotech subsidiary has received US Food…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi ARIA

BioTrends views Xeljanz and Zytiga prescribing in USA


After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

Phenex in up to $135 million research collaboration with Janssen


Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

Janssen files Stelara for active psoriatic arthritis in USA and EU


US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen yesterday submitted a supplemental…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationStelara Injection

Highlights of ACR meeting include new Cimzia, Stelara and Simponi data


Belgian drugmaker UCB (UCB: BR) presented results for Cimzia (certolizumab pegol), from the Phase III…

Anti-Arthritics/RheumaticsCimziaJohnson & JohnsonPharmaceuticalResearchSimponi InjectionStelara InjectionUCB

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA


US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

Janssen files BLA for IV form of Simponi for moderate-to-severe RA


US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech has submitted a Biologics…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Janssen initiates Ph III study of sirukumab, being developed with GSK


Janssen Biologics (Ireland), part of US health care giant Johnson & Johnson (NYSE: JNJ), has initiated…

Anti-Arthritics/RheumaticsGlaxoSmithKlineJanssenJohnson & JohnsonPharmaceuticalResearchsirukumab

More news at EULAR from Novartis, J&S and B-MS


Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

FDA approves Alexion’s Soliris for rare pediatric blood disorder and J&J’s Remicade for children with UC


The US Food and Drug Administration on Friday approved Alexion Pharmaceuticals’ (Nasdaq: ALXN) Soliris…

Alexion PharmaceuticalsAnti-Arthritics/RheumaticsJohnson & JohnsonNorth AmericaPharmaceuticalRare diseasesRegulationRemicadeSolaris

Janssen Biotech gets FDA delay for new Simponi indication


The US Food and Drug Administration has issued a Complete Response letter (CRL) to Janssen Biotech, a…

Anti-Arthritics/RheumaticsBiotechnologyJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Back to top